G1 Therapeutics buy krebskrebs
Start price
21.08.23
/
50%
€1.63
Target price
21.08.24
€3.00
Performance (%)
133.97%
Price
24.05.24
€3.77
Summary
This prediction is currently active. The BUY prediction by krebskrebs for G1 Therapeutics has seen massive gains of 133.97%. This prediction currently runs until 21.08.24. The prediction end date can be changed by krebskrebs at any time. krebskrebs has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| G1 Therapeutics | -9.515% | -9.515% |
| iShares Core DAX® | -0.205% | 2.949% |
| iShares Nasdaq 100 | 1.613% | 5.877% |
| iShares Nikkei 225® | -0.740% | -1.256% |
| iShares S&P 500 | 0.267% | 3.240% |